Self-amplifying mRNA Will Meet Aging Global Therapy Demand
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 9 Analysts
Published
22 Aug 25
Updated
22 Aug 25
AnalystHighTarget's Fair Value
US$132.96
86.1% undervalued intrinsic discount22 Aug
US$18.51
1Y
-13.7%7D
3.4%